Anticipated at a compound annual growth rate of approximately 4% from 2020 onwards, the market for cancer-supportive care products shows promising expansion. Erythropoietin-stimulating agents are positioned to capture the largest share of revenue, owing to their proven effectiveness in addressing anemia induced by c.
The Bone Growth Stimulators Market size is predicted to be worth US$ 2.1 billion in 2023, rising to US$ 5.4 billion by 2033. During the projected period, sales of Bone Growth Stimulators are expected to expand at a substantial CAGR of 10.1%. Growth in the market is attributed to the rising overall fracture injuries.